BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations ...Middle East

- Study will assess bemcentinib in combination with current standard of care for 1st line NSCLC - - Approximately 20% of NSCLC patients have STK11 mutations - - First patient is expected to be dosed in 4Q22 - BERGEN, Norway, Oct. 11, 2022 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a...

Hence then, the article about bergenbio announces initiation of phase 1b 2a trial evaluating bemcentinib in 1st line non small cell lung cancer patients harboring stk11 mutations was published today ( Tuesday 11/10/2022 - 08:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations )

Also on site :

• Canadian tourist tests positive ​for hantavirus after leaving luxury cruise ship ‌hit by outbreak
• 'Grey's Anatomy' Star Opens Up About Eric Dane's Death: 'I Was Just Sobbing'
• 1982 Hit Short Film, Originally Banned in United States, Became a Timeless Classic